13D Filing: Theorem Group, LLC Discloses Agreement with Oxis International Inc (OXIS)

Page 1 of 5

At Insider Monkey, we closely monitor the moves made by activist investors. Their targets are often undervalued stocks with firm foundations that for one reason or another have failed to execute. At times, all it takes is a fresh outlook and a slight tweak to completely alter the makeup and efficiency of a company, and activists can provide this. They also shine a spotlight on shareholder value creation, which can be neglected by entrenched management who often have their priorities elsewhere. Below and on the following pages we have embedded the latest 13D activist filing related to Oxis International Inc (OTCMKTS:OXIS), which was recently submitted by Theorem Group, LLC. Among other things, the filing sheds light on a recent warrant exercise agreement reached between the two parties and other shareholders of Oxis International.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Theorem Group, LLC 2,096,480 2,096,480 9.9%
Anshuman Dube 2,096,480 2,096,480 9.9%

Page 1 of 5 SEC Filing



Washington, D.C. 20549

(Amendment No. 2)

Under the Securities Exchange Act of


(Name of Issuer)

Common Stock, $0.001 Par Value Per Share

(Title of Class of Securities)


(CUSIP Number)

Anshuman Dube

Theorem Group, LLC

315 S. Beverly Drive, Suite 502

Beverly Hills, California 90212

(310) 500,2155

(Name, Address and Telephone Number of Person
Authorized to Receive Notice and Communications)

January 8, 2016

(Date of Event Which Requires Filing of
this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d–1(e),
240.13d–1(f) or 240.13d–1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See Rule 13d–7 for other parties to whom copies are to
be sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Gt Biopharma Inc.

Page 1 of 5